| Epidemiology from Literature | | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | | 1.10 - Any allergy symptom, Diagnosed | 2010 | Belgium | IgE | 86 | 11.620 | 20101214, Gadisseur R
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | France | IgE | 61 | 16.390 | 20100923, Codrenau F
| | 1.11 - Esophagitis, Diagnosed | 2013 | Netherlands | IgE | 76 | 1.300 | 20131020, van Rhijn BD
| | 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 1.040 | 20120528, Patelis A
| | 1.3 - Rhinitis, Diagnosed | 2013 | Brazil | IgE | 101 | 0.900 | 20130912, Lacerda Araujo LM
| | 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | BPT | 20 | 5.000 | 20091005, Ott H
| | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Netherlands | IgE | 211 | 7.600 | 20140331, Rockmann H
| | 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 0.000 | 20110223, De Knop KJ
| | 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 0.000 | 20091121, Ebo DG
| | 3.1.1 - Source Sensitized (SPT) | 2012 | Spain | IgE | 79 | 8.860 | 20121016, Javaloyes G
| | 3.1.4 - Source Sensitized (SPT, IgE) | 2013 | Netherlands | IgE | 22 | 27.270 | 20130429, Aalberse JA
| | 3.1.4 - Source Sensitized (SPT, IgE) | 2012 | Spain | IgE | 68 | 7.400 | 20120726, Pedrosa M
| | 3.2.1 - Source Sensitized (IgE) | 2014 | France | IgE | 68 | 32.000 | 20141107, Agabriel C
| | 3.2.1 - Source Sensitized (IgE) | 2014 | Germany | IgE | 27 | 55.550 | 20140225, Lopes de Oliveira LC
| | 3.2.1 - Source Sensitized (IgE) | 2013 | Italy | IgE | 24 | 17.000 | 20131128, Calamelli E
| | 3.2.1 - Source Sensitized (IgE) | 2013 | Slovenia | IgE | 16 | 6.250 | 20131106, Homsak M
| | 3.2.1 - Source Sensitized (IgE) | 2010 | Sweden | IgE | 100 | 25.000 | 20100212, Asarnoj A
| | 3.2.1 - Source Sensitized (IgE) | 2013 | Thailand | IgE | 21 | 9.500 | 20131011, Suratannon N
| | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 2011 | China | IgE | 100 | 0.000 | 20111214, Zheng YW
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2010 | Belgium | IgE | 20 | 35.000 | 20100628, Verweij MM
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 0.000 | 20091121, Ebo DG
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 0.000 | 20091121, Ebo DG
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2010 | Sweden | IgE | 50 | 0.000 | 20100212, Asarnoj A
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 0.000 | 20090826, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Italy | IgE | 21 | 0.000 | 20090808, Krause S
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2011 | Netherlands | IgE | 8 | 0.000 | 20110304, Vissers YM
| | 5.1.1 - Source Exposed (Symptoms) | 2013 | Netherlands | IgE | 37 | 56.760 | 20130428, Klemans RJ
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 12.120 | 20110223, De Knop KJ
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | France | IgE | 68 | 46.000 | 20141107, Agabriel C
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Germany | IgE | 32 | 78.120 | 20140225, Lopes de Oliveira LC
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2013 | Italy | IgE | 24 | 29.000 | 20131128, Calamelli E
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Japan | IgE | 16 | 87.500 | 20140623, Nozawa A
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2013 | Slovenia | IgE | 11 | 63.630 | 20131106, Homsak M
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2010 | Spain | IgE | 50 | 16.000 | 20101124, Vereda A
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2011 | Sweden | IgE | 74 | 44.590 | 20110701, Moverare R
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2010 | Sweden | IgE | 35 | 37.100 | 20101124, Vereda A
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2013 | Thailand | IgE | 19 | 21.100 | 20131011, Suratannon N
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2010 | United States | IgE | 30 | 56.700 | 20101124, Vereda A
| | 5.3.2 - Source Exposed (Symptoms, high IgE) | 2012 | Taiwan | IgE | 29 | 62.100 | 20120319, Lin YT
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2013 | Netherlands | IgE | 43 | 39.540 | 20130429, Aalberse JA
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2011 | Netherlands | IgE | 12 | 66.660 | 20110304, Vissers YM
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2004 | Netherlands / Switzerland | IgE | 17 | 52.900 | 20041204, Mittag D
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2012 | Spain | IgE | 55 | 43.600 | 20120726, Pedrosa M
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2004 | Netherlands | IgE (IB) | 32 | 37.500 | 20040416, Koppelman SJ
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 2006 | France | IgE | 30 | 20.000 | 20060630, Astier C
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 1999 | Germany | IgE (IB) | 40 | 53.000 | 1999, Kleber-Janke T
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 2006 | France | SPT | 30 | 27.000 | 20060630, Astier C
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2010 | France | IgE | 166 | 61.450 | 20100923, Codrenau F
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2013 | Italy | IgE | 48 | 23.000 | 20131128, Calamelli E
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2007 | Netherlands | IgE | 20 | 50.000 | 20070615, Flinterman AE
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2013 | Sweden / USA | IgE | 167 | 34.200 | 20130113, Lieberman JA
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 1999 | United States | IgE | 18 | 44.400 | 1999, Rabjohn P
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2007 | Netherlands | SPT | 9 | 55.500 | 20070615, Flinterman AE
| | 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 0.000 | 20120528, Patelis A
|
|
Loading...
Ara h 3
